Injectafer

Ferric Carboxymaltose, the active ingredient in Injectafer, is an iron supplement presented as an injection solution for intravenous infusion. It treats iron deficiency anemia in adults, including patients with chronic kidney disease, inflammatory bowel disease, and postpartum women.

GNH USA supplies Injectafer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Injectafer is used to correct iron deficiency anemia across several clinical contexts.

- Iron deficiency anemia in adults: restores hemoglobin levels and improves functional capacity. - Iron deficiency anemia in chronic kidney disease: provides readily available iron for patients receiving dialysis or erythropoiesis‑stimulating agents. - Iron deficiency anemia in inflammatory bowel disease: compensates for malabsorption and chronic blood loss. - Iron deficiency anemia in postpartum women: rapidly replenishes iron stores after childbirth.

Injectafer may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea or vomiting - Headache or dizziness - Injection‑site pain, erythema, or swelling - Transient hypotension or flushing - Metallic taste or dysgeusia - Mild fever or chills

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Severe hypotension or shock - Acute respiratory distress syndrome (ARDS) - Hypophosphatemia leading to muscle weakness or bone pain - Cardiac arrhythmias in susceptible patients - Severe liver enzyme elevations

Before using Injectafer, clinicians should consider several safety measures.

- Assess iron status: confirm iron deficiency before infusion. - Monitor during infusion: observe for hypersensitivity or cardiovascular changes. - Infusion rate: avoid rapid administration to reduce risk of hypotension. - Infection risk: use cautiously in patients with active infections. - Compatibility: do not mix with calcium‑containing solutions or other incompatible IV drugs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Injectafer can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent high‑dose oral iron supplements: may reduce IV iron efficacy and increase gastrointestinal irritation. - Erythropoiesis‑stimulating agents (ESAs) without iron monitoring: risk of iron overload.

Moderate Interactions (Monitor Closely): - Tetracycline antibiotics: potential chelation reducing antibiotic absorption. - Antacids containing aluminum or magnesium: may affect iron complex stability. - Calcium channel blockers: monitor for additive hypotensive effects during infusion.